J Aisner, MY Whitacre, DR Budman… - Cancer …, 1992 - researchwithrutgers.com
Because of potential synergistic interactions, we added 25 mg/m 2 iv cisplatin (P) 25 given on days 1-5 to the combination of 45 mg/m 2 iv doxorubicin (A) given on day 1, 800 mg/m 2 …
J Aisner, MY Whitacre, DR Budman… - Cancer …, 1992 - pubmed.ncbi.nlm.nih.gov
Because of potential synergistic interactions, we added 25 mg/m2 iv cisplatin (P) 25 given on days 1-5 to the combination of 45 mg/m2 iv doxorubicin (A) given on day 1, 800 mg/m2 iv …
J Aisner, MY Whitacre, DR Budman… - Cancer …, 1992 - europepmc.org
Because of potential synergistic interactions, we added 25 mg/m2 iv cisplatin (P) 25 given on days 1-5 to the combination of 45 mg/m2 iv doxorubicin (A) given on day 1, 800 mg/m2 iv …
J AISNER, MY WHITACRE… - Cancer …, 1992 - pascal-francis.inist.fr
Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …
[引用][C]Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer
J AISNER, MY WHITACRE, DR BUDMAN… - Cancer chemotherapy …, 1992 - Springer
[引用][C]Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer
J Aisner, MY Whitacre, DR Budman, K Propert… - Cancer Chemotherapy …, 1992 - Springer